317 related articles for article (PubMed ID: 29218272)
1. Blood-based biomarkers in lung cancer: prognosis and treatment decisions.
Xu-Welliver M; Carbone DP
Transl Lung Cancer Res; 2017 Dec; 6(6):708-712. PubMed ID: 29218272
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
4. Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.
Matikas A; Syrigos KN; Agelaki S
Clin Lung Cancer; 2016 Nov; 17(6):507-516. PubMed ID: 27373516
[TBL] [Abstract][Full Text] [Related]
5. Blood-based tumor biomarkers in lung cancer for detection and treatment.
Mamdani H; Ahmed S; Armstrong S; Mok T; Jalal SI
Transl Lung Cancer Res; 2017 Dec; 6(6):648-660. PubMed ID: 29218268
[TBL] [Abstract][Full Text] [Related]
6. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
7. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
8. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.
Riethdorf S; Soave A; Rink M
Transl Androl Urol; 2017 Dec; 6(6):1090-1110. PubMed ID: 29354496
[TBL] [Abstract][Full Text] [Related]
9. The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments.
Di Capua D; Bracken-Clarke D; Ronan K; Baird AM; Finn S
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439082
[TBL] [Abstract][Full Text] [Related]
10. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.
Manicone M; Poggiana C; Facchinetti A; Zamarchi R
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1346-S1358. PubMed ID: 29184673
[TBL] [Abstract][Full Text] [Related]
11. Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.
Yang J; Hui Y; Zhang Y; Zhang M; Ji B; Tian G; Guo Y; Tang M; Li L; Guo B; Ma T
Front Oncol; 2021; 11():725938. PubMed ID: 34422670
[TBL] [Abstract][Full Text] [Related]
12. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
Morrison GJ; Goldkorn A
Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
14. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
Ilie M; Hofman V; Long E; Bordone O; Selva E; Washetine K; Marquette CH; Hofman P
Ann Transl Med; 2014 Nov; 2(11):107. PubMed ID: 25489581
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
16. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.
Pérez-Callejo D; Romero A; Provencio M; Torrente M
Transl Lung Cancer Res; 2016 Oct; 5(5):455-465. PubMed ID: 27826527
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
